A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Heckmann, Jeannine M ^a   Rawoot, Amanullah ^a   Bateman, Kathleen ^a   Renison, Rudi ^a   Badri, Motasim ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FOLIC ACID; METHOTREXATE; PREDNISONE; PYRIDOSTIGMINE; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADULT; AFRICA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY NEUROSIS; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DAILY LIFE ACTIVITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; ERYTHEMA; FATIGUE; FEMALE; FOOT EDEMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEARING LOSS; HEART PALPITATION; HIRSUTISM; HUMAN; HYPERAMYLASEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INSOMNIA; LEG CRAMP; MALE; MOOD; MOON FACE; MOUTH ULCER; MYASTHENIA GRAVIS; MYCOSIS; OUTCOME ASSESSMENT; PNEUMONIA; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; STEROID THERAPY; STOMACH ULCER; SUPPURATIVE HIDRADENITIS; THYMECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISONE; SINGLE-BLIND METHOD;

EID: 79961117546     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-97     Document Type: Article

References (33)

1. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007, CD005224.
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8(5):475-90. 10.1016/S1474-4422(09)70063-8, 2730933, 19375665.
3. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998, 50:1778-83.
4. Bateman KJ, Schinkel M, Little F, Liebenberg L, Vincent A, Heckmann JM. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S Afr Med J 2007, 97:959-62.
5. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003, 61:1652-61.
6. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009, 68:1094-99. 10.1136/ard.2008.092668, 2689521, 19033290.
7. Mertens HG, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969, 2:321-39. 10.1159/000113809, 4185500.
8. Pruitt JN, Swift TR. Therapies for disorders of the neuromuscular junction. Arch Neurol 2002, 59:739-42. 10.1001/archneur.59.5.739, 12020254.
9. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004, 29:484-505. 10.1002/mus.20030, 15052614.
10. Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 2007, 7:405-11. 10.1136/jnnp.2007.134130, 18024782.
11. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991, 34:961-72. 10.1002/art.1780340805, 1859490.
12. Seideman P. Methotrexate--the relationship between dose and clinical effect. Br J Rheumatol 1993, 32:751-53. 10.1093/rheumatology/32.8.751, 8348281.
13. Schnabel A, Reinhold-Keller E, Willmann V, Gross WL. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis. Rheumatol Int 1994, 14:33-8. 10.1007/BF00302669, 7939138.
14. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003, 35:619-27. 10.1016/S1590-8658(03)00372-4, 14563183.
15. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998, 841:769-72. 10.1111/j.1749-6632.1998.tb11015.x, 9668327.
16. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000, 55:16-23.
17. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 1999, 52:1487-89.
18. Heckmann JM, Owen EP, Little F. Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuromuscul Disord 2007, 17:929-34. 10.1016/j.nmd.2007.07.002, 17720497.
19. Aban IB, Wolfe GI, Cutter GR, et al. The MGTX experience: challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol 2008, 201-202:80-84. 2654214, 18675464.
20. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001, 134:695-706.
21. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989, 32:121-7. 10.1002/anr.1780320202, 2920047.
22. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987, 316:719-24. 10.1056/NEJM198703193161205, 3547126.
23. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008, 37:141-9. 10.1002/mus.20950, 18059039.
24. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:423-6. 10.1136/ard.62.5.423, 1754533, 12695153.
25. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001, 44:1515-24. 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7, 11465701.
26. Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol 2009, 160:622-8. 10.1111/j.1365-2133.2008.08876.x, 18945303.
27. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998, 102:322-8. 10.1172/JCI2676, 508890, 9664073.
28. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001, 167:2911-2920.
29. Neurath MF, Hildner K, Becker C, et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999, 115:42-55. 10.1046/j.1365-2249.1999.00753.x, 1905174, 9933419.
30. Bijlsma JW, Weinblatt ME. Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis 2007, 66:1409-10. 10.1136/ard.2007.076463, 2111621, 17934080.
31. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002, 59:1844-50.
32. Chaudhuri A, Behan PO. Myasthenic crisis. Q J Med 2009, 102:97-107.
33. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology 2008, 71:1639-43. 10.1212/01.wnl.0000336535.27773.c0, 19001255.